News
Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...
The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
5don MSN
The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...
Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results